Tumor Activity Articles & Analysis: Older
62 news found
Mutations in the TP53 gene reduce the tumor suppressor activity of the encoded P53 protein. They are present in approximately half of all human malignancies, including breast, colorectal, lung, liver, prostate, bladder and skin cancers. ...
“Tulmimetostat was designed to target both EZH2-related tumor progression and the redundant actions of EZH1 with high potency and durability, along with additional pharmacokinetic advances over prior EZH2 inhibitors, offering the potential for enhanced anti-tumor activity across numerous cancer types,” said Tim Demuth, M.D., Ph.D., ...
The financing will be used to advance NextPoint’s two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. ...
ByBayer AG
About Pelabresib Pelabresib (CPI-0610) is an investigational selective small molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain (BET) proteins to decrease the expression of abnormally expressed genes in cancer. ...
By blocking the nuclear export protein XPO1, XPOVIO® can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulating proteins, and down-regulate the levels of multiple oncogenic proteins. XPOVIO® delivers its antitumor effects through three mechanistic pathways: 1) exerting antitumor effects by inducing the ...
Also presented were translational data from MANIFEST indicating the association of biomarkers with potential disease-modifying activity of pelabresib. The findings were presented during two oral sessions at the 64th American Society of Hematology (ASH 2022) Annual Meeting and Exposition in New Orleans, Louisiana. ...
Title: Treatment of anti-SIRPα in combination with anti-TAA exerts superior anti-tumor activity Abstract No.: 793 SIRPα is an inhibitory receptor expressed mainly on myeloid cells and dendritic cells. ...
CD73 generates adenosine, which leads to immunosuppression in the tumor microenvironment. ATG-037 has demonstrated promising preclinical efficacy as a monotherapy and in combination with ICIs and chemotherapy agents. ...
RGT-264 phosphate tablet is a highly potent and selective HPK1 inhibitor. HPK1 kinase activity suppresses the immune functions of a wide range of cells including T cells and dendritic cells (DCs) 1. Therefore, inhibiting HPK1 activity serves as a promising approach for cancer immunotherapy. Currently, there is no HPK1 inhibitor approved globally. The phase 1 ...
By blocking the nuclear export protein XPO1, XPOVIO® can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulating proteins, and down-regulate the levels of multiple oncogenic proteins. XPOVIO® delivers its antitumor effects through three mechanistic pathways: 1) exerting antitumor effects by inducing the ...
Title: ES005, a high affinity anti-LAG3 monoclonal antibody, inhibits the interactions between LAG3 and multiple ligands and enhances anti-tumor activity of T cells in preclinical models Abstract No.: 426 Date and time: 11/11/2022, 9:00 am - 9:00 pm (EST) 2. ...
In animal models, LB-100 has consistently enhanced the anti-tumor activity of doxorubicin without apparent increases in toxicity. ...
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile. In preclinical studies, ATG-101 ...
In animal models, sCD80 was well-tolerated and stopped tumor growth by potentially restoring natural anti-tumor immunity (see Lucas A Horn, et al . and Samuel T Haile et al. in collaboration with Dr. Ostrand-Rosenberg). Additionally, strong anti-tumor activity of sCD80 has been reported in multiple tumor types ...
“We are humbled by the work in front of us in partnership with Roche as we explore the anti-tumor activity of our immunotherapy candidate in combination with atezolizumab to see if our exciting results in 1st line maintenance therapy can be extended to advanced stage disease by the use of this combination of ...
In addition to enhancing the differentiation and yield of immune cells within the manufacturing process, our RACR™ system should bring therapeutic benefit to patients, allowing for safe in vivo engraftment and persistence of tumor-killing cells without requirements for toxic lymphodepleting ...
AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational status Study demonstrated specific anti-tumor response even at low levels of CD123 expression with no evidence for off-target cytotoxic activity towards CD123-negative healthy bone marrow progenitors In ...
HB-200 was generally well tolerated, rapidly induced a high magnitude of tumor-specific T cells and showed early anti-tumor activity in these difficult-to-treat patients. ...
Furthermore, AFM28 induced lysis of CD123-positive tumor cells when pre-complexed or when co-administered with cryopreserved NK cells, suggesting that AFM28 in combination with NK cells maintains anti-tumor activity, an exciting finding in that it presents the promise for an off-the-shelf therapy targeting leukemic blasts and LSCs in patients ...
Phase 1 data show single-vector HB-201 and 2-vector HB-202/HB-201 were generally well tolerated, rapidly induced tumor-specific T cells and showed anti-tumor activity in heavily pre-treated head and neck cancer patients Poster presentation to include data supporting recommended Phase 2 dose for alternating 2-vector HB-202/HB-201 and Phase 2 ...